Androlic Oxymetholone 50 mg

• Brand: The British Dispensary Co. LTD
• Category: Oral AAS Research Compound
• Content: 100 tablets | 50 mg per tablet
• Manufactured in: Thailand

Product Overview

Oxymetholone 50 mg, commercially known as ANDROLIC, is a structurally modified

17--alkylated dihydrotestosterone (DHT) derivative developed for hematologic and androgen-receptor (AR)

modulation research. Its strong anabolic index, erythropoietic activity, and well-documented hepatic risk profile

make it a key reference standard in studies of AR signaling, EPO regulation, and steroid toxicology.

Originally used clinically for anemia, oxymetholone has shown notable increases in erythropoietin (EPO),

red-cell mass, and protein-synthesis pathways. Its 17--alkylated structure enhances oral bioavailability

while elevating hepatotoxicity risk, supporting reproducible liver-injury modeling.

Key Research Highlights

Enhanced erythropoiesis:

FDA and NCBI data confirm increased erythropoietin and hematologic output.

Potent AR agonism:

Strong anabolic transcriptional signaling suitable for AR-targeted assays.

High oral stability with hepatic strain:

17--alkylation increases bioavailability but introduces significant hepatotoxicity.

Endocrine & metabolic effects:

Dyslipidemia, suppression of endogenous hormones, fluid retention, and virilization endpoints.

Suggested Laboratory Applications

• Hematologic stimulation modeling (EPO & red-cell regulation)
• Androgen receptor activation & gene-transcription studies
• Anabolic-androgenic steroid toxicology
• Hepatic injury modeling (peliosis, cholestasis, tumor pathways)
• Comparative anabolic potency benchmarks

Technical Specifications

Documented Benefits

EPO, red-cell mass, anabolic transcription, protein synthesis

Main Risks

Hepatotoxicity (peliosis, tumors), cholestasis, dyslipidemia, endocrine suppression, edema

Detection Considerations

WADA S1 classification — prohibited in all doping contexts

Shelf-life

36 months

PubChem-Supported Research Insights

• Strong AR agonist with high transcriptional activity
• Enhances erythropoietin through androgen-mediated signaling
• Marked hepatic strain due to 17--alkylation
• Valuable as a toxicology reference in steroid metabolism studies
• Affects lipid regulation and endocrine pathways

Documented Research Side Effects

• Hepatic tumors, peliosis hepatis, cholestatic jaundice (FDA warnings)
• Dyslipidemia ( LDL / HDL)
• Edema and altered fluid retention
• Suppression of endogenous testosterone
• Virilization endpoints in androgen-sensitive models

Handling & Compliance

For Research Use Only — Not for human or veterinary application.

Store dry, protected from light, below 30 °C.

Listed under WADA S1 prohibited anabolic agents.

Purchase confirms qualified researcher status.